Document And Entity Information (Abstract) Document And Entity Information [Abstract] Statement [Table] Statement [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Trading Symbol Entity Filer Category Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets [Abstract] Assets Abstract ASSETS Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Cash and cash equivalents at beginning of period Cash and cash equivalents Cash and cash equivalents Marketable Securities, Current Marketable securities Marketable Securities, Total Amounts classified as marketable securities, Estimated Fair Value Prepaid Expense and Other Assets, Current Prepaids and other current assets Prepaid Expense and Other Assets, Current, Total Assets, Current Total current assets Property and equipment, net Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property and equipment, net Other Assets, Noncurrent Deposits and other assets Other Assets, Noncurrent, Total Assets Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable Accounts Payable, Current, Total Carrying value as of the balance sheet date of obligations incurred through that date and payable, pertaining to costs that are related to clinical trials for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued clinical expense, current Accrued clinical expense Employee-related Liabilities, Current Accrued compensation Employee-related Liabilities, Current, Total Other accrued liabilities Notes Payable, Current Current portion of notes payable Notes Payable, Current, Total Derivative Liabilities Current Ending Balance Beginning Balance Warrant liability Product Warranty Accrual, Total Total estimated fair value of outstanding warrants Liabilities, Current Total current liabilities Notes Payable, Noncurrent Non-current portion of notes payable Notes Payable, Noncurrent, Total Non-current portion of deferred rent Non-current portion of deferred rent Commitments Stockholders' equity: Common Stock Value Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common stock Common Stock, Value, Issued, Total Additional Paid in Capital, Common Stock Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated deficit Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Accumulated deficit Stockholders' Equity Attributable to Parent Ending balance Beginning balance Total stockholders' equity Liabilities and Stockholders' Equity BS Total liabilities and stockholders' equity Condensed Consolidated Statements Of Comprehensive Income (Loss) [Abstract] Revenue: License revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark (i.e. 'intellectual property'). This element includes (i) licensing revenue recognized in the period under licensing arrangements (including upfront license or technology transfer fees, milestone payments and royalty payments), (ii) revenues recognized from the outright sale of intellectual property, and (iii) any other revenues not separately presented elsewhere in the statements of comprehensive income (loss). License And Other Revenue License and other revenue Total revenues Total revenues Operating expenses: Research and development Research and development General and administrative General and administrative Total operating expenses Total operating expenses Loss from operations Loss from operations Interest Expense Interest expense Interest expense Interest Expense, Total Other Nonoperating Income (Expense) Other income (expense), net Other Nonoperating Income (Expense), Total Net income (loss) Net income (loss) Net income (loss) Net loss Available-for-sale Securities, Change in Net Unrealized Holding Gain (Loss), Net of Tax Unrealized gain (loss) on available-for-sale securities Available-for-sale Securities, Change in Net Unrealized Holding Gain (Loss), Net of Tax, Total Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income (loss) Earnings Per Share, Basic and Diluted [Abstract] Net income (loss) per common share: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Shares used in computing net income (loss) per common share: Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Income (Loss) Per Common Share [Abstract] Net income (loss) per common share: Earnings Per Share, Basic Basic Earnings Per Share, Basic, Total Earnings Per Share, Diluted Diluted Earnings Per Share, Diluted, Total Condensed Consolidated Statements Of Cash Flows [Abstract] Cash flows from operating activities Adjustments to reconcile income (loss) to net cash used in operating activities Adjustments to reconcile income (loss) to net cash used in operating activities: Stock-based compensation expense Stock-based compensation expense Depreciation and amortization Depreciation and amortization Amortization of Financing Costs and Discounts Amortization of debt discount and debt issuance costs Amortization of Financing Costs and Discounts, Total Increase Decrease in Derivative Assets and Liabilities Change in fair value of warrant liability Change in fair value of warrant liability included in other income (expense) Non-cash credit for revaluation of warrant liability Increase (Decrease) in Derivative Assets and Liabilities, Total Change in fair value of warrant liability included in other income (expense) The gain (loss) recorded during the reporting period resulting from changes in the value of marketable securities denominated in foreign currencies as a result of movements in the related exchange rates. Exchange Gain Loss on Marketable Securities Foreign exchange gain on marketable securities Exchange gain on marketable securities Other Noncash Income (Expense) Other non-cash items Other non-cash items Other Noncash Income (Expense), Total Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Accounts receivable Increase (Decrease) in Prepaid Expense and Other Assets Prepaids and other assets Prepaids and other current assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase Decrease In Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total The net change during the reporting period in the obligations incurred and payable, pertaining to costs that are related to clinical trials for which invoices have not yet been received or will not be rendered. Increase Decrease In Accrued Clinical Expense Accrued clinical expense Increase (Decrease) in Employee Related Liabilities Accrued compensation Increase (Decrease) in Employee Related Liabilities, Total IncreaseDecreaseInOtherAccruedLiabilities Other accrued liabilities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash flows from investing activities Purchases of property and equipment Purchases of property and equipment Purchases of property and equipment Purchases of marketable securities Purchases of marketable securities Purchases of marketable securities Proceeds from maturities of marketable securities Proceeds from maturities of marketable securities Proceeds from maturities of marketable securities Net Cash Provided by (Used in) Investing Activities Net cash provided by investing activities Cash flows from financing activities Proceeds from issuance of common stock through equity facilities net. Proceeds from Issuance of Common Stock through Equity Facilities Net Proceeds from issuance of common stock through controlled equity offering facilities, net Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options Proceeds from exercise of stock options and employee stock purchase plans Proceeds from exercise of stock options and from employee stock purchase plan Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net decrease in cash and cash equivalents Company Overview [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Company Overview Summary Of Significant Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Summary Of Significant Accounting Policies Earnings Per Share [Text Block] Income (Loss) Per Common Share Royalty Agreement [Abstract] Royalty agreement [Text Block]. Royalty Agreement [Text Block] Royalty Agreement Notes Payable [Abstract] Debt Disclosure [Text Block] Notes Payable Financial Instruments [Abstract] Financial Instruments Disclosure [Text Block] Financial Instruments Stockholders' Equity [Abstract] Stockholders Equity Note Disclosure Text Block Stockholders' Equity Stock-Based Compensation [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation